Takeda Pharmaceuticals LLC (Takeda Russia) is celebrating the fifth anniversary of its plant in Yaroslavl. This advanced pharmaceutical enterprise built in 2012 was created “from scratch” as part of an investment project worth more than 75 million euro.
Today, Takeda plant is one of the key members of Yaroslavl pharmaceutical cluster. Its capacity allows full-cycle production of up to 60 million ampoules and more than 3 billion tablets a year.
Since the launch of the plant, all its products meet Russian and international GMP requirements. Takeda plant was one of the first pharmaceutical enterprises in Russia that have received Russian GMP certificate. The plant also implemented the system of compliance with international quality standards established at the enterprises of the company across the world.
“New challenges faced by the plant require new approaches. We are constantly improving in order to lead in terms of compliance with GMP standards and meet the growing demands of industry and the market. Our priority will always be the quality of products,” said Maciej Fabiańczyk, the Director of Takeda plant in Yaroslavl. “Currently, all our efforts are focused on the upcoming launch of facility for innovative medicines, which required to build “from scratch” new manufacturing sites and expand the capacity; as well as on implementing new labeling, within a state pilot project, for all products produced by the plant.”